Surgery Partners (NASDAQ:SGRY) Rating Lowered to Neutral at Mizuho

Surgery Partners (NASDAQ:SGRY) was downgraded by equities researchers at Mizuho from an “outperform” rating to a “neutral” rating in a research note issued on Wednesday, FinViz reports. They currently have a $25.00 price target on the stock, up from their previous price target of $19.00. Mizuho‘s target price indicates a potential downside of 6.47% from the company’s current price.

SGRY has been the topic of a number of other research reports. Weiss Ratings upgraded shares of Surgery Partners from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 16th. UBS Group cut shares of Surgery Partners from a “buy” rating to a “hold” rating and increased their price objective for the stock from $21.00 to $23.50 in a research report on Wednesday, October 28th. Zacks Research downgraded shares of Surgery Partners from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 10th. Raymond James Financial set a $23.50 target price on shares of Surgery Partners in a research note on Monday, October 26th. Finally, Royal Bank Of Canada boosted their target price on shares of Surgery Partners from $23.50 to $25.00 and gave the company a “sector perform” rating in a report on Tuesday. Two investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $20.10.

Surgery Partners Trading Up 1.1%

NASDAQ SGRY opened at $26.73 on Wednesday. The firm has a market capitalization of $3.50 billion, a PE ratio of -39.31 and a beta of 1.85. The business’s 50-day moving average price is $16.55 and its two-hundred day moving average price is $14.94. The company has a current ratio of 1.95, a quick ratio of 1.78 and a debt-to-equity ratio of 1.18. Surgery Partners has a 12 month low of $11.41 and a 12 month high of $27.23.

Surgery Partners (NASDAQ:SGRY) last posted its quarterly earnings data on Monday, November 9th. The company reported $0.16 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.05. Surgery Partners had a positive return on equity of 0.96% and a negative net margin of 2.59%. The company had revenue of $815.30 million for the quarter, compared to analyst estimates of $820.96 million. During the same period in the previous year, the firm earned $0.13 earnings per share. The firm’s quarterly revenue was down .8% on a year-over-year basis. On average, analysts expect that Surgery Partners will post 0.07 EPS for the current year.

Insider Activity

In other Surgery Partners news, Director Teresa DeLuca purchased 10,000 shares of the business’s stock in a transaction on Tuesday, August 18th. The shares were purchased at an average cost of $14.35 per share, for a total transaction of $143,500.00. Following the acquisition, the director owned 66,843 shares of the company’s stock, valued at approximately $959,197.05. This represents a 17.59% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 2.00% of the company’s stock.

Institutional Trading of Surgery Partners

Several hedge funds have recently modified their holdings of the stock. Jupiter Topco LLC acquired a new position in shares of Surgery Partners during the 2nd quarter valued at $233,220,000. Pentwater Capital Management LP acquired a new stake in Surgery Partners in the second quarter worth $195,384,000. BlackRock Inc. acquired a new stake in Surgery Partners in the second quarter worth $104,857,000. Hsbc Holdings PLC bought a new stake in Surgery Partners in the second quarter valued at $48,912,000. Finally, Bank of America Corp DE bought a new stake in Surgery Partners in the second quarter valued at $20,374,000.

Key Surgery Partners News

Here are the key news stories impacting Surgery Partners this week:

• Positive Sentiment: The merger price was raised to $25 per share after a rival bid emerged. Reports say a Bon Secours affiliate’s offer could be worth up to $6 billion, and RBC suggested a revised competing offer is possible. The prospect of a higher bid has supported investor interest; however, the referenced $25 terms are below the $26.73 share price in the provided market data, leaving deal uncertainty. RBC on possible revised rival offer
• Positive Sentiment: Third-quarter adjusted EPS was $0.16, above estimates of $0.07–$0.11 and up from $0.13 a year earlier. Q3 earnings report
• Neutral Sentiment: RBC raised its price target from $23.50 to $25 but kept a “sector perform” rating. The higher target is still below the supplied share price, while RBC’s comments about a possible revised rival offer leave room for further deal developments.
• Negative Sentiment: Quarterly revenue of $815.3 million missed estimates and declined slightly year over year. The company also reported a $21.1 million net loss attributable to common shareholders, with weaker gross and operating profit—offset in part by improved operating cash flow.
• Negative Sentiment: Law firms announced investigations into the proposed transaction, raising questions about whether shareholders are receiving fair value. Such scrutiny could add uncertainty or delay; it does not establish wrongdoing. Shareholder buyout investigation notice

About Surgery Partners

Surgery Partners, Inc. is a U.S. healthcare services company that owns and operates ambulatory surgery centers and surgical hospitals. Its facilities provide outpatient and inpatient surgical care across a range of specialties. The company’s services include surgical procedures and related care delivered in partnership with physicians and healthcare professionals. Its network serves patients in multiple states across the United States. Founded in 2004, Surgery Partners has expanded its network through acquisitions and partnerships with physicians and health systems.